PCM
KALA icon

Prelude Capital Management’s KALA BIO KALA Stock Holding History

Prelude Capital Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3
Closed -$67K – 1904
2019
Q1 		$67K Buy
+3
New +$53.3K ﹤0.01% 1056
2018
Q2 		– Sell
-28
Closed -$1.12M – 1793
2018
Q1 		$1.12M Buy
28
+25
+833% +$949K 0.08% 250
2017
Q4 		$131K Buy
+3
New +$140K 0.01% 724

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's KALA Position: Q2 2019 in Review

Prelude Capital Management sold out of KALA BIO (KALA) in Q2 2019, closing a stake of 3 shares — an estimated $67K sold.

Prelude Capital Management first reported a position in KALA in Q4 2017 and held it in 3 quarters. The position peaked at $1.12M in Q1 2018. 63 funds tracked by Wall St. Rank hold KALA as of Q2 2019.

  • Prelude Capital Management reported no remaining KALA BIO position as of Q2 2019 after selling out during the quarter.
  • Prelude Capital Management sold 3 KALA BIO shares in Q2 2019, an estimated $67K.
  • Prelude Capital Management first reported a position in KALA BIO in Q4 2017 and held it in 3 quarters.
  • Prelude Capital Management's KALA BIO position peaked at $1.12M in Q1 2018.
  • 63 funds tracked by Wall St. Rank held KALA BIO as of Q2 2019.

Based on Prelude Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.